NATCO PHARMA LTD. - 524816 - Un-Audited Financial Results For The Quarter Ended 30Th June, 2019
Un-audited Financial Results for the quarter ended 30th June, 201909-08-2019
09-08-2019
Inspection of Natco unit complete
Natco Pharma Ltd has announced successful completion of inspection by USFDA of its formulations plant at Kothur in Telangana. The US Food and Drug Ad05-08-2019
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
NATCO RECEIVES ESTABLISHMENT INSPECTION REPORT FOR KOTHUR FACILITY05-08-2019
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call with Investors / Analysts at 3.30 p.m. IST on August 9,2019 to disseminate Financial Results of the company for the quarter ended June 30, 201902-08-2019
Natco Pharma Ltd - 524816 - Board Meeting Intimation for To Consider Un-Audited Results For The Quarter Ended June 30, 2019 And Interim Dividend For The FY 19-20
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2019 ,inter alia, to consider and approve To consider un-audited results for the quarter ended June 30, 2019 and interim dividend for the FY 19-2031-07-2019
Company news: Natco Pharma
Natco Pharma has announced the successful completion of regulatory inspection by the US Food and Drug Administration of its active pharmaceutical ingr15-07-2019
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO COMPLETES USFDA INSPECTION FOR CHENNAI API FACILITY WITH ZERO OBSERVATIONS15-07-2019
NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance letter under Reg.74(5) of SEBI (D) Regulations, 2011 for the quarter ended 30th June, 201911-07-2019
Natco Pharma Ltd - 524816 - Shareholding for the Period Ended June 30, 2019
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly Click here09-07-2019
NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Venkata Satya Swathi Kantamani05-07-2019